Evaluating Magnetic Seed Localization in Targeted Axillary Dissection for Node-Positive Early Breast Cancer Patients...

Area of Science:

• Oncology
• Surgical Oncology
• Breast Cancer Research

Background:

• Advancements in neoadjuvant systemic therapy (NST) and localization technologies enable de-escalation of axillary surgery.
• Magseed® is a wire-free localization technology for lymph node retrieval and staging.
• Targeted axillary dissection (TAD), including marked lymph node biopsy (MLNB) and sentinel lymph node biopsy (SLNB), is crucial for assessing residual disease post-NST.

Purpose of the Study:

• To evaluate the performance of Magseed® in targeted axillary dissection (TAD).
• To assess Magseed®'s efficacy in localizing and retrieving lymph nodes for staging in breast cancer patients post-NST.

Main Methods:

• Systematic review and pooled analysis of nine studies involving 494 patients.
• Assessment of Magseed® localization and retrieval rates, concordance between MLNB and SLNB, and pathological complete response (pCR).
• Data sourced from PubMed and Google Scholar.

Main Results:

• 100% deployment rate, 94.2% localization rate, and 98.8% retrieval rate for Magseed®.
• 68.8% concordance rate between MLNB and SLNB; 47.9% pCR observed.
• Lower false negative rate (FNR) for MLNB (4.2%) compared to SLNB (17.6%).

Conclusions:

• Magseed® magnetic seed localization demonstrates efficacy in TAD for NST-treated node-positive breast cancer patients.
• Facilitates accurate axillary pCR identification, supporting safe de-escalation of axillary surgery.
• Effective for identifying residual disease in excellent responders to NST.